GRO Biosciences
GRO Biosciences innovates protein therapeutics using novel amino acids to combat incurable diseases.
Founded
2016GRO Biosciences innovates protein therapeutics using novel amino acids to combat incurable diseases.
GRO Biosciences, founded with the mission to revolutionize protein therapeutics, focuses on utilizing novel amino acids to develop treatments for previously incurable diseases. The company offers innovative solutions through its proprietary GRO Platform and ProGly™ programs, which enhance the therapeutic potential of proteins. GRO Biosciences aims to address significant unmet medical needs by leveraging advanced bioengineering techniques to create more effective and durable protein-based therapies.
Notable figures affiliated with GRO Biosciences include leading scientists and industry experts who contribute to its groundbreaking research and development efforts. The company has attracted investment from prominent biotech venture capital firms, underscoring its potential and credibility in the market. Key achievements include successful preclinical studies demonstrating the efficacy of their novel therapeutics. GRO Biosciences is poised to make a substantial impact on the field of protein therapeutics, offering hope for patients with diseases that currently lack effective treatments.
Companies similar to GRO Biosciences include Grove Biopharma, Groove Biopharma, AI Proteins and ProFound Therapeutics.
GRO Biosciences was founded in 2016.
GRO Biosciences' headquarters is located in Boston, MA, US.
GRO Biosciences' most recent funding round was for $25M (USD) in November 2021.
As of Nov 1, 2021, GRO Biosciences has disclosed funding of $32.3M (USD). Undisclosed round amounts are excluded.
GRO Biosciences has 44 employees as of Feb 5, 2024.
ProFound Therapeutics
profoundtx.com
